Access and affordability of medicines are top priority issues for healthcare stakeholders globally. Discussions in recent years have focused on the availability and use of recently launched medicines. Among those medicines are some that can be considered “essential” on the basis that at least one similar drug in a therapeutic group has been reviewed and received public reimbursement in at least half of the European countries assessed. To date, limited evidence has been presented to show per capita use across countries and for each of the clusters or groups of these Essential Innovative Medicines (EIMs).
This report has been prepared to provide evidence and context to discussions of medicine access and use in Europe. It draws upon research undertaken at the IQVIA Institute and other parts of IQVIA and taps IQVIA’s extensive global data assets that measure the use of medicines and their costs.
Use our interactive infographic to explore average per capital Essential Innovative Medicine use in Europe across therapy clusters and countries.